Jeffrey Bernstein
About Jeffrey Bernstein
Jeffrey Bernstein is a Business Development Manager specializing in Gene Therapy CDMO Services at Andelyn Biosciences, where he has worked since 2021. He has a strong background in drug discovery and development, with notable achievements in securing multimillion-dollar contracts in the life sciences sector.
Work at Andelyn Biosciences
Jeffrey Bernstein serves as the Business Development Manager for Gene Therapy CDMO Services at Andelyn Biosciences. He has held this position since 2021, contributing to the company's growth in Columbus, Ohio. In his role, he has successfully secured significant contracts, including a $660,000 agreement for GMP Tox AAV material. His responsibilities include identifying new business opportunities and fostering relationships within the gene therapy sector.
Education and Expertise
Jeffrey Bernstein holds a Bachelor of Science in Biology from Eastern Michigan University and a Master of Science in Biology from Long Island University. His educational background supports his extensive experience in drug discovery and development, particularly in immuno-oncology and genomics sequencing and analysis. This foundation in biology enhances his ability to navigate complex scientific discussions and contribute to business development in the life sciences.
Background
Bernstein has a diverse professional background, having worked in various capacities within the life sciences sector. He began his career as a Research Scientist at Memory Pharmaceuticals from 2001 to 2005. He has since held several managerial and director-level positions, including roles at Biocytogen Boston Corporation, Syngene International Limited, and WuXi AppTec. His experience spans both large and small molecule drug development, showcasing his adaptability in the industry.
Achievements
Throughout his career, Jeffrey Bernstein has demonstrated a strong ability to establish multimillion-dollar territories in the life sciences sector. Notably, he closed a $5.5 million contract in 2021 for the scale-up engineering, non-clinical (GLP Tox), and GMP manufacture of a viral vector for gene therapy. His track record highlights his effectiveness in bridging technical and business teams to drive new business opportunities.